GlassScriptPhysician profile
Stephanie Pearson Meyer
NPI 1790045870
$4,675.25
in general payments reported to CMS, 2019-2025
34 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $909 · 2021: $1,056 · 2022: $527 · 2023: $858 · 2024: $551 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $841.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $656.03 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $589.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $316.61 | 2020-2024 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $221.09 | 2019-2023 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $200.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $187.26 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Abbvie INC. | $185.32 | 2021-2024 | |
| Astellas Pharma US INC | $164.69 | 2019-2025 | Veozah |
| Abbott Laboratories | $162.83 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $119.50 | 2021-2025 | |
| Amarin Pharma, INC. | $113.47 | 2020-2021 | |
| Boston Scientific Corporation | $98.73 | 2021-2024 | Bionic Navigator |
| Sanofi-Aventis U.S. LLC | $91.68 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.97 | 2022-2024 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $73.80 | 2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.96 | 2021-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $58.52 | 2019-2022 | |
| Corcept Therapeutics | $51.20 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $44.94 | 2020-2021 | |
| Allergan, INC. | $36.80 | 2019-2022 | |
| Vivus LLC | $36.45 | 2021-2023 | Qsymia |
| Avanir Pharmaceuticals, INC. | $35.60 | 2021 | |
| Eisai INC. | $32.86 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $31.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.38 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.18 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $20.28 | 2022 | |
| Amgen INC. | $20.18 | 2025 | Otezla, Repatha |
| Tactile Systems Technology INC | $19.43 | 2023 | Entre Plus, Flexitouch Plus |
| Horizon Therapeutics Plc | $18.41 | 2020 | |
| Sanofi Pasteur INC. | $17.69 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.